New therapy for anaemic myelodysplastic cancer patients
Reblozyl, the first erythroid maturation agent showed increased haemoglobin in transfusion-dependant patients with myelodysplastic syndromes.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
